<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>JCAD &#187; 09-2008 (September 2008)</title>
	<atom:link href="http://www.jcadonline.com/category/issue-archives/09-2008-september-2008/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.jcadonline.com</link>
	<description>The Journal of Clinical and Aesthetic Dermatology (JCAD)</description>
	<lastBuildDate>Mon, 19 Jul 2010 21:02:58 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0</generator>
		<item>
		<title>Topical Imiquimod Therapy for Actinic Keratosis Is Long-Term Clearance a Realistic Benefit?</title>
		<link>http://www.jcadonline.com/topical-imiquimod-therapy-for-actinic-keratosis-is-long-term-clearance-a-realistic-benefit/</link>
		<comments>http://www.jcadonline.com/topical-imiquimod-therapy-for-actinic-keratosis-is-long-term-clearance-a-realistic-benefit/#comments</comments>
		<pubDate>Tue, 16 Sep 2008 23:42:47 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[09-2008 (September 2008)]]></category>
		<category><![CDATA[Actinic Keratosis]]></category>
		<category><![CDATA[Questions-Challenges-Controversies]]></category>
		<category><![CDATA[Challenges]]></category>
		<category><![CDATA[Questions]]></category>

		<guid isPermaLink="false">http://nearmyth.com/jcad/?p=492</guid>
		<description><![CDATA[by James Q. Del Rosso, DO, FAOCD Dr. James Del Rosso, DO, FAOCD, is Dermatology Residency Director, Valley Hospital Medical Center; Clinical Associate Professor (Dermatology), University of Nevada School of Medicine, Las Vegas, Nevada; and Associate Professor (Dermatology), Touro University College of Osteopathic Medicine, Henderson, Nevada. Topical imiquimod, available as a 5% cream, is approved [...]]]></description>
		<wfw:commentRss>http://www.jcadonline.com/topical-imiquimod-therapy-for-actinic-keratosis-is-long-term-clearance-a-realistic-benefit/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
